<?xml version='1.0' encoding='utf-8'?>
<document id="31384555"><sentence text="Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease." /><sentence text="We report a case of concurrent development of active pulmonary tuberculosis and invasive pulmonary aspergillosis (IPA) in a patient who received therapy with infliximab for Crohn's disease" /><sentence text=" He has been treated with antitubercular therapy and liposomal amphotericin B for 8 weeks"><entity charOffset="63-77" id="DDI-PubMed.31384555.s3.e0" text="amphotericin B" /></sentence><sentence text=" His clinical course was complicated by paroxysmal atrial fibrillation requiring maintenance therapy with amiodarone, respiratory failure due both to pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamases (ESBL)-producing Klebsiella pneumoniae and pleural effusion requiring chest drainage"><entity charOffset="106-116" id="DDI-PubMed.31384555.s4.e0" text="amiodarone" /><entity charOffset="170-181" id="DDI-PubMed.31384555.s4.e1" text="methicillin" /><pair ddi="false" e1="DDI-PubMed.31384555.s4.e0" e2="DDI-PubMed.31384555.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31384555.s4.e0" e2="DDI-PubMed.31384555.s4.e1" /></sentence><sentence text=" At discharge, a maintenance regimen based on the administration of isavuconazole 200 mg daily, moxifloxacin 400 mg daily and isoniazid 300 mg daily was chosen to avoid multiple drug-drug interaction between rifamycins, antifungal triazole agents and antiarrhythmic drugs"><entity charOffset="68-81" id="DDI-PubMed.31384555.s5.e0" text="isavuconazole" /><entity charOffset="96-108" id="DDI-PubMed.31384555.s5.e1" text="moxifloxacin" /><entity charOffset="126-135" id="DDI-PubMed.31384555.s5.e2" text="isoniazid" /><entity charOffset="208-218" id="DDI-PubMed.31384555.s5.e3" text="rifamycins" /><entity charOffset="231-239" id="DDI-PubMed.31384555.s5.e4" text="triazole" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e0" e2="DDI-PubMed.31384555.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e0" e2="DDI-PubMed.31384555.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e0" e2="DDI-PubMed.31384555.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e0" e2="DDI-PubMed.31384555.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e0" e2="DDI-PubMed.31384555.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e1" e2="DDI-PubMed.31384555.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e1" e2="DDI-PubMed.31384555.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e1" e2="DDI-PubMed.31384555.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e1" e2="DDI-PubMed.31384555.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e2" e2="DDI-PubMed.31384555.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e2" e2="DDI-PubMed.31384555.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e2" e2="DDI-PubMed.31384555.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e3" e2="DDI-PubMed.31384555.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31384555.s5.e3" e2="DDI-PubMed.31384555.s5.e4" /></sentence><sentence text=" At 3 months of follow-up his clinical conditions were dramatically improved, high resolution chest tomography (HRCT) showed reduction of parenchymal lesions and no changes both in sinus rhythm and QTc interval were noticed" /><sentence text=" Besides the complexity and the peculiarity of the clinical scenario, this case underlines the risk of invasive fungal infections linked to the administration of TNF-α antagonists in gastroenterological setting and the importance of accurate evaluation of drug-drug interactions when choosing the antimicrobial therapies" /><sentence text="" /></document>